All In Biotech

Drug Trial Radar · NCT05904470

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

275

Actual

Start

May 30, 2023

Primary completion

Dec 9, 2024

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Conditions

  • Chronic Hepatitis C Virus
  • Hepatitis C, Chronic
  • Hepatitis C
  • Hepatic Cirrhosis
  • HCV

Interventions

  • BemnifosbuvirDrug

    550 mg administered orally once a day (QD) for 8 weeks

  • RuzasvirDrug

    180 mg administered orally once a day (QD) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)Time frame: Day 1 through 12 weeks after end of treatment

Locations

51 sites in 12 countries. Site status is shown where the registry gives one.

  • Atea Study Site

    San Antonio, Texas

  • Atea Study Site

    Manaus, Amazonas, Brazil

  • Atea Study Site

    Salvador, Estado de Bahia, Brazil

  • Atea Study Site

    Brasília, Federal District, Brazil

  • Atea Study Site

    Rio de Janeiro, Rio Do Janeiro, Brazil

  • Atea Study Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Atea Study Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Atea Study Site

    Porto Velho, Rondônia, Brazil

  • Atea Study Site

    Boa Vista, Roraima, Brazil

  • Atea Study Site

    Botucatu, São Paulo, Brazil

  • Atea Study Site

    Ijuí, São Paulo, Brazil

  • Atea Study Site

    São José do Rio Preto, São Paulo, Brazil

  • Atea Study Site

    São Paulo, São Paulo, Brazil

  • Atea Study Site

    São Paulo, São Paulo, Brazil

  • Atea Study Site

    Sorocaba, São Paulo, Brazil

  • Atea Study Site

    Vancouver, British Columbia, Canada

  • Atea Study Site

    Toronto, Ontario, Canada

  • Atea Study Site

    Rajkot, Gujarat, India

  • Atea Study Site

    Surat, Gujarat, India

  • Atea Study Site

    Belagavi, Karnataka, India

  • Atea Study Site

    Nagpur, Maharashtra, India

  • Atea Study Site

    Kolkata, West Bengal, India

  • Atea Study Site

    Quatre Bornes, Mauritius

  • Atea Study Site

    Chisinau, Moldova

  • Atea Study Site

    Karachi, Pakistan

  • Atea Study Site

    Karachi, Pakistan

  • Atea Study Site

    Baguio City, Philippines

  • Atea Study Site

    Iloilo City, Philippines

  • Atea Study Site

    Mabalacat, Philippines

  • Atea Study Site

    Bucharest, Romania

  • Atea Study Site

    Bucharest, BUC, Romania

  • Atea Study Site

    Bucharest, BUC, Romania

  • Atea Study Site

    Constanța, CON, Romania

  • Atea Study Site

    Craiova, DOL, Romania

  • Atea Study Site

    Bloemfontein, Free State, South Africa

  • Atea Study Site

    Johannesburg, Gauteng, South Africa

  • Atea Study Site

    Randburg, Gauteng, South Africa

  • Atea Study Site

    Somerset West, Western Cap, South Africa

  • Atea Study Site

    Busan, South Korea

  • Atea Study Site

    Busan, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.